Last reviewed · How we verify
NCT03074175
Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01)
NA trial testing radiotherapy in Advanced Nsclc in 240 participants. Completed in 31 December 2019.
1 August 2019
Quick facts
| Lead sponsor | Xinqiao Hospital of Chongqing |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 240 |
| Start date | 1 July 2017 |
| Primary completion | 1 August 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- radiotherapy — full drug profile →
Conditions studied
- Advanced Nsclc — all drugs for Advanced Nsclc →
Sponsor
Xinqiao Hospital of Chongqing
Who can join
Adults 18 to 75, any sex, with Advanced Nsclc. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lung cancer is a malignant tumor that causes the highest morbidity and mortality, and the main pathological type is non-small cell lung cancer (NSCLC). Most of them present with advanced stage at diagnosis. Radiotherapy is an important treatment strategy for advanced non-small cell lung cancer. However patients have different responses to radiotherapy due to individual differences, thus there is still lacking of sensitive markers to predict treatment response at present. Using bioinformatics to process the data and small sample clinical trial, our previous study found 5 plasma miRNAs were related to radiosensitivity. The design is controlled clinical trial. According to the size of lung lesions, the investigators divided the patients into hyperfractionated radiotherapy group（50Gy/11F/2W) with lesion ≤5cm in diameter and conventional fractionated radiotherapy group（60Gy/30F/6W）with lesion \>5cm in diameter.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting non-coding RNAs to overcome cancer therapy resistance.
Chen B, Dragomir MP, Yang C, Li Q, et al · · 2022 · cited 324× · PMID 35418578 · DOI 10.1038/s41392-022-00975-3 -
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027 -
MicroRNA in lung cancer-a novel potential way for early diagnosis and therapy.
Frydrychowicz M, Kuszel Ł, Dworacki G, Budna-Tukan J. · · 2023 · cited 24× · PMID 36821071 · DOI 10.1007/s13353-023-00750-2 -
Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: from regulatory mechanisms to clinical implications.
Long L, Zhang X, Bai J, Li Y, et al · · 2019 · cited 16× · PMID 31191004 · DOI 10.2147/cmar.s198966 -
Exosomal microRNA Therapy for Non-Small-Cell Lung Cancer.
Chen J, Wu F, Hou E, Zeng J, et al · · 2023 · cited 9× · PMID 37936417 · DOI 10.1177/15330338231210731
Verify or expand the search:
- PubMed search for NCT03074175
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of radiotherapy
Trials testing the same drug.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
- NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
- NCT07282483 — Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer P · Phase 2 · recruiting
- NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
Other Xinqiao Hospital of Chongqing trials
Trials by the same sponsor.
- NCT07347626 — Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis · Phase 3 · not yet recruiting
- NCT07349836 — Application of mRNA Immunotherapy Technology in EB Virus Related Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07362758 — Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07349849 — Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies · EARLY_PHASE1 · recruiting
- NCT06987305 — Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03074175 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xinqiao Hospital of Chongqing
- Last refreshed: 5 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03074175.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing